Reposted by POTS Radar
Regeneron is recruiting for a phase 2 RCT of REGN7544 (an NPR1 antagonist mAb) for POTS. They’re seeking 81 patients in Pasadena, CA; Carlsbad, CA; Nashville, TN; and Clearwater, FL clinicaltrials.gov/study/NCT065...
clinicaltrials.gov
ClinicalTrials.gov